Status: Recruiting
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).
Participants needed: 104
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Centauri Therapeutics LimitedUpdated: Jul 16, 2026Locations: 1
Eligibility criteria
Parts A and B: Healthy adult males and/or females, 18 to 65 years of age. [+6]
Parts A and B: Previous participation in the current trial. [+9]